MCID: CHR064
MIFTS: 39

Chronic Monocytic Leukemia

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Chronic Monocytic Leukemia

MalaCards integrated aliases for Chronic Monocytic Leukemia:

Name: Chronic Monocytic Leukemia 12 14
Leukemia, Monocytic, Chronic 69
Leukemia, Myeloid 42

Classifications:



External Ids:

Disease Ontology 12 DOID:8593
ICD10 33 C93.1 C92
ICD9CM 35 206.1
MeSH 42 D007951
NCIt 47 C34774
UMLS 69 C0023466

Summaries for Chronic Monocytic Leukemia

MalaCards based summary : Chronic Monocytic Leukemia, also known as leukemia, monocytic, chronic, is related to myeloid leukemia and myeloid/lymphoid or mixed lineage leukemia. An important gene associated with Chronic Monocytic Leukemia is C3 (Complement C3), and among its related pathways/superpathways are Sertoli-Sertoli Cell Junction Dynamics and Focal Adhesion. The drugs Aldesleukin and Asparaginase have been mentioned in the context of this disorder. Affiliated tissues include myeloid, monocytes and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and hematopoietic system

Related Diseases for Chronic Monocytic Leukemia

Diseases in the Monocytic Leukemia family:

Acute Monocytic Leukemia Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Chronic Monocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
id Related Disease Score Top Affiliating Genes
1 myeloid leukemia 11.5
2 myeloid/lymphoid or mixed lineage leukemia 11.0
3 leukemia, acute myeloid 10.9
4 leukemia, chronic myeloid, somatic 10.9
5 atypical chronic myeloid leukemia 10.9
6 partial circumpapillary choroid dystrophy 10.5 C3 MPO
7 follicular mucinosis 10.5 ITGAM MPO
8 dermatomycosis 10.5 C3 MPO
9 dislocation of ear ossicle 10.4 C3 MPO
10 extrahepatic biliary papillomatosis 10.4 CD34 MPO
11 thymus small cell carcinoma 10.4 F2 PTPRC
12 filamentary keratitis 10.4 CD34 PTPRC
13 vestibule of mouth cancer 10.4 CD34 PTPRC
14 coronary aneurysm 10.4 CD34 PTPRC
15 dermoid cyst 10.4 CD34 PTEN
16 salivary gland adenoid cystic carcinoma 10.3 CD34 PTPRC
17 tropical spastic paraparesis 10.3 CD34 PTEN
18 pericoronitis 10.3 CD34 PTPRC
19 fallopian tube squamous cell carcinoma 10.3 CD34 PTPRC
20 heel spur 10.3 CD34 PTPRC
21 dense deposit disease 10.3 MPO PTPRC
22 brain stem infarction 10.3 CD34 PTPRC
23 hemopneumothorax 10.3 CD34 F2
24 cholesteatoma 10.3 MPO PTPRC
25 sphenoid sinusitis 10.3 C3 MPO
26 atrophic vulva 10.2 C3 F2 MPO
27 bronchiolo-alveolar adenocarcinoma 10.2 CD34 F2
28 central nervous system mature teratoma 10.2 CD34 MPO
29 van maldergem syndrome 2 10.2 C3 F2
30 basilar artery insufficiency 10.1 F2 ITGAM MPO
31 acneiform dermatitis 10.1 CD34 PTPRC
32 lymphomatous thyroiditis 10.1 ITGAM ITGAX
33 hepatocellular adenoma 10.0 F2 MPO
34 leukemia 10.0
35 monocytic leukemia 10.0
36 gallbladder cancer 9.9 CD34 F2 PTEN
37 psychosexual disorder 9.8 F2 ITGAM
38 myocardial infarction 9.6 CD34 F2 ITGAM MPO
39 smoking as a quantitative trait locus 1 9.4 CD34 ITGAX PTPRC
40 cranioectodermal dysplasia 1 8.9 CD34 ITGAM ITGAX MPO PTPRC
41 gum cancer 6.2 C3 CD34 F2 ITGAD ITGAM ITGAX

Graphical network of the top 20 diseases related to Chronic Monocytic Leukemia:



Diseases related to Chronic Monocytic Leukemia

Symptoms & Phenotypes for Chronic Monocytic Leukemia

GenomeRNAi Phenotypes related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 9.44 PTPRC
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.44 ITGAM
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.44 ITGAM
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.44 PTPRC
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 9.44 PTPRC
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.44 PTPRC
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 9.44 PTEN
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.44 PTPRC
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.44 F2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 9.44 PTEN PTPRC F2 ITGAM

MGI Mouse Phenotypes related to Chronic Monocytic Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.81 C3 CD34 F2 ITGAD ITGAM ITGAX
2 homeostasis/metabolism MP:0005376 9.61 C3 CD34 F2 ITGAD ITGAM LGALS1
3 immune system MP:0005387 9.32 C3 CD34 F2 ITGAD ITGAM ITGAX

Drugs & Therapeutics for Chronic Monocytic Leukemia

Drugs for Chronic Monocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
2
Asparaginase Approved Phase 3 9015-68-3
3
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
4
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
5
Cytarabine Approved, Investigational Phase 3,Phase 1,Phase 2 147-94-4 6253
6
Daunorubicin Approved Phase 3 20830-81-3 30323
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
8
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
9
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
10
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
11
Idarubicin Approved Phase 3,Phase 1,Phase 2 58957-92-9 42890
12
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
13
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
14
Thioguanine Approved Phase 3 154-42-7 2723601
15
Hydroxyurea Approved Phase 3 127-07-1 3657
16
Mitoxantrone Approved, Investigational Phase 3,Phase 1 65271-80-9 4212
17
Azacitidine Approved, Investigational Phase 3,Phase 1 320-67-2 9444
18
Clofarabine Approved, Investigational Phase 3,Phase 1 123318-82-1 119182
19
Decitabine Approved, Investigational Phase 3,Phase 1 2353-33-5 451668
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
21
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
22
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538
23
Butyric Acid Experimental Phase 3 107-92-6 264
24 Alkylating Agents Phase 3,Phase 2,Phase 1
25 Analgesics Phase 3,Phase 1,Phase 2
26 Analgesics, Non-Narcotic Phase 3,Phase 1,Phase 2
27 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
28 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
29 Antiemetics Phase 3,Phase 2
30 Anti-HIV Agents Phase 3,Phase 1,Phase 2
31 Anti-Infective Agents Phase 3,Phase 2,Phase 1
32 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
33 Antimetabolites Phase 3,Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
35 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
36 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
37 Anti-Retroviral Agents Phase 3,Phase 1,Phase 2
38 Antirheumatic Agents Phase 3,Phase 2,Phase 1
39 Antiviral Agents Phase 3,Phase 1,Phase 2
40 Autonomic Agents Phase 3,Phase 2
41 BB 1101 Phase 3
42 Cortisol succinate Phase 3
43 Dermatologic Agents Phase 3,Phase 2,Phase 1
44 Dexamethasone acetate Phase 3 1177-87-3
45 Etoposide phosphate Phase 3,Phase 2,Phase 1
46 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
47 Gastrointestinal Agents Phase 3,Phase 2
48 glucocorticoids Phase 3,Phase 2,Phase 1
49 Hormone Antagonists Phase 3,Phase 2,Phase 1
50 Hormones Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 55)

id Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
2 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
3 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
4 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
5 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
6 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
7 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
8 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
9 Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia Completed NCT00079313 Phase 2 Imatinib
10 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
11 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
12 Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT01020734 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate
13 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
14 MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia Completed NCT00462605 Phase 2 entinostat;sargramostim
15 Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome Completed NCT00002547 Phase 2 busulfan;cyclophosphamide;cyclosporine;cytarabine;methotrexate
16 Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00004896 Phase 2 busulfan;cyclophosphamide
17 Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00004899 Phase 2 busulfan;etoposide
18 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
19 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
20 A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) Recruiting NCT03040401 Phase 1, Phase 2 Cohort 1, Ceplene® and Proleukin®;Cohort 2, Ceplene® and Proleukin®;Cohort 3, Ceplene® and Proleukin®
21 Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission Active, not recruiting NCT00045435 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
22 Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia Terminated NCT00006092 Phase 2 Arsenic Trioxide
23 Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Terminated NCT00555048 Phase 1, Phase 2 busulfan;cyclophosphamide;methotrexate;tacrolimus
24 Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant Terminated NCT01118013 Phase 2 busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus
25 Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes Completed NCT00098423 Phase 1 tanespimycin;cytarabine
26 Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00217646 Phase 1 Sorafenib Tosylate
27 Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia Completed NCT00131989 Phase 1 sorafenib tosylate
28 Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders Completed NCT00293410 Phase 1 clofarabine;cyclophosphamide
29 SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes Completed NCT00098826 Phase 1 ispinesib
30 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes Completed NCT00301938 Phase 1 7-hydroxystaurosporine;perifosine
31 Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia Completed NCT00053144 Phase 1 cytarabine;irinotecan hydrochloride
32 Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase Completed NCT00383474 Phase 1 Bortezomib;Tipifarnib
33 Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00258271 Phase 1 cladribine;cytarabine;imatinib mesylate
34 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome Completed NCT00077558 Phase 1 fludarabine phosphate;triapine
35 Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia Completed NCT00002588 Phase 1 etoposide;topotecan hydrochloride
36 Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders Completed NCT00114257 Phase 1 decitabine;romidepsin
37 Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders Completed NCT00357305 Phase 1 vorinostat;cytarabine;etoposide
38 XK469R in Treating Patients With Refractory Hematologic Cancer Completed NCT00095797 Phase 1 R(+)XK469
39 Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005092 Phase 1 Cyclophosphamide;Psoralen;Thiotepa
40 Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome Completed NCT00005593 Phase 1 carboplatin;fludarabine phosphate;topotecan hydrochloride
41 Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer Completed NCT00003395 Phase 1 arsenic trioxide
42 Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer Completed NCT00304018 Phase 1 busulfan;etoposide;fludarabine phosphate;prednisone;tacrolimus
43 Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia Recruiting NCT01801046 Phase 1 mitoxantrone hydrochloride;cytarabine
44 Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders Active, not recruiting NCT00588991 Phase 1 Carboplatin;Topotecan Hydrochloride;Veliparib
45 Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Active, not recruiting NCT01849276 Phase 1 metformin hydrochloride;cytarabine
46 Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia Terminated NCT00101231 Phase 1 alvocidib
47 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients Terminated NCT02137889 Phase 1 VAY736
48 Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia Terminated NCT01159301 Phase 1 entinostat;sorafenib tosylate
49 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer Terminated NCT00103272 Phase 1 tanespimycin;bortezomib
50 Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT01831232 pravastatin sodium;idarubicin;cytarabine

Search NIH Clinical Center for Chronic Monocytic Leukemia

Cochrane evidence based reviews: leukemia, myeloid

Genetic Tests for Chronic Monocytic Leukemia

Anatomical Context for Chronic Monocytic Leukemia

MalaCards organs/tissues related to Chronic Monocytic Leukemia:

39
Myeloid, Monocytes, Bone, Bone Marrow

Publications for Chronic Monocytic Leukemia

Articles related to Chronic Monocytic Leukemia:

id Title Authors Year
1
Partial cytogenetic response with toceranib and prednisone treatment in a young dog with chronic monocytic leukemia. ( 23995854 )
2013
2
BCR-ABL translocation in a dog with chronic monocytic leukemia. ( 21143615 )
2011
3
Chronic monocytic leukemia terminating in blastic transformation. ( 3465380 )
1986
4
Chronic monocytic leukemia in adults. ( 6945897 )
1981
5
Chronic monocytic leukemia. ( 276262 )
1978
6
Chronic monocytic leukemia: a case with an eight-year survival. ( 5240097 )
1967
7
Chronic monocytic leukemia in childhood. ( 13576375 )
1958

Variations for Chronic Monocytic Leukemia

Expression for Chronic Monocytic Leukemia

Search GEO for disease gene expression data for Chronic Monocytic Leukemia.

Pathways for Chronic Monocytic Leukemia

Pathways related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

(show all 21)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.68 ITGAD ITGAM ITGAX PTEN
2
Show member pathways
12.65 ITGAD ITGAM ITGAX PTEN
3
Show member pathways
12.62 ITGAD ITGAM ITGAX PTEN
4 12.34 F2 ITGAD ITGAM ITGAX
5 12.23 CD34 LGALS1 MPO PTPRC
6
Show member pathways
12.18 ITGAD ITGAM ITGAX
7
Show member pathways
12 F2 ITGAM ITGAX
8 11.99 C3 ITGAM ITGAX
9
Show member pathways
11.92 ITGAD ITGAM ITGAX PTEN
10 11.91 C3 ITGAM MPO
11
Show member pathways
11.89 ITGAD ITGAM ITGAX
12 11.85 CD34 ITGAM PTPRC
13
Show member pathways
11.8 C3 ITGAM ITGAX
14 11.7 ITGAD ITGAM ITGAX
15 11.7 C3 F2 ITGAM ITGAX
16 11.62 CD34 ITGAM PTPRC
17 11.45 CD34 ITGAM PTPRC
18 11.39 C3 ITGAD ITGAM ITGAX
19 11.25 ITGAD ITGAM ITGAX
20 11.14 CD34 ITGAM ITGAX PTPRC
21 11.09 CD34 ITGAM ITGAX MPO PTPRC

GO Terms for Chronic Monocytic Leukemia

Cellular components related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.33 CD34 F2 PTPRC
2 integrin complex GO:0008305 9.13 ITGAD ITGAM ITGAX
3 cell surface GO:0009986 9.1 CD34 ITGAD ITGAM ITGAX LGALS1 PTPRC

Biological processes related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.71 CD34 ITGAD ITGAM ITGAX
2 cellular protein metabolic process GO:0044267 9.54 C3 F2 LGALS1
3 extracellular matrix organization GO:0030198 9.5 ITGAD ITGAM ITGAX
4 integrin-mediated signaling pathway GO:0007229 9.33 ITGAD ITGAM ITGAX
5 heterotypic cell-cell adhesion GO:0034113 9.26 ITGAD ITGAX
6 leukocyte migration GO:0050900 9.26 CD34 F2 ITGAM ITGAX
7 neutrophil degranulation GO:0043312 9.02 C3 ITGAM ITGAX MPO PTPRC

Sources for Chronic Monocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....